95 results
6-K
EX-99.1
GLPG
Galapagos NV
30 May 24
Current report (foreign)
4:44pm
Litigation Reform Act of 1995, as amended. These statements are often, but are not always, made through the use of words or phrases such as “anticipate
6-K
EX-99.1
GLPG
Galapagos NV
16 May 24
Current report (foreign)
8:11am
Securities Litigation Reform Act of 1995, as amended. These statements are often, but are not always, made through the use of words or phrases
6-K
EX-99.1
GLPG
Galapagos NV
8 Apr 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
9:27am
statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended
6-K
EX-99.5
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
RELATING TO TECHNICAL GUARANTEES IN RESPECT OF SALES OR SERVICES
Period
AMOUNT, NATURE AND FORM CONCERNING LITIGATION AND OTHER IMPORTANT COMMITMENTS
43/57
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
not or will not infringe the patents or other intellectual property rights of third parties. There is significant litigation activity in the pharmaceutical … industry regarding patent and other intellectual property rights. Such litigation could result in substantial costs and be a distraction to management
6-K
EX-99.1
3r7lzc 2ulg4r7g3n82
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
6-K
EX-99.1
v8ak3onl5vz
6 Feb 24
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6:00am
6-K
EX-99.1
f9a60z2iy5idlnb
4 Jan 24
Current report (foreign)
5:32pm
6-K
EX-99.1
tmjpf3xylo vg
4 Jan 24
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
4:07pm
6-K
EX-99.1
k9u6x4t iowgs
4 Jan 24
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
4:05pm
6-K
EX-99.1
wv4zt1dgtma
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm
6-K
EX-99.1
v0ad7jq0 ar
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
6-K
EX-99.1
ma8yw mu9qg4pig
12 Dec 23
Current report (foreign)
6:00am
6-K
EX-99.1
oci8hjgi0o04
2 Nov 23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
7:15am
6-K
EX-99.1
76h qxq87
15 Jun 23
Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
5:03pm
6-K
EX-99.1
phc9o0 6xv4cfk06c8
2 May 23
Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer
4:49pm
6-K
EX-99.1
kwxbc3ra
23 Dec 22
Galapagos announces changes to Executive Committee
6:05am
6-K
EX-99.1
l4c5zaycr7qsak9
31 May 22
Current report (foreign)
1:39pm
6-K
EX-99.1
tre5f7bhlx2
28 Mar 22
Jyseleca® approved in Japan for ulcerative colitis
1:50pm